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Abstract
Arrhythmogenic cardiomyopathy (ACM) is hallmarked by ventricu-
lar fibro-adipogenic alterations, contributing to cardiac dysfunc-
tions and arrhythmias. Although genetically determined (e.g.,
PKP2 mutations), ACM phenotypes are highly variable. More data
on phenotype modulators, clinical prognosticators, and etiological
therapies are awaited. We hypothesized that oxidized low-density
lipoprotein (oxLDL)-dependent activation of PPARc, a recognized
effector of ACM adipogenesis, contributes to disease pathogene-
sis. ACM patients showing high plasma concentration of oxLDL
display severe clinical phenotypes in terms of fat infiltration,
ventricular dysfunction, and major arrhythmic event risk. In ACM
patient-derived cardiac cells, we demonstrated that oxLDLs are
major cofactors of adipogenesis. Mechanistically, the increased
lipid accumulation is mediated by oxLDL cell internalization
through CD36, ultimately resulting in PPARc upregulation. By
boosting oxLDL in a Pkp2 heterozygous knock-out mice through
high-fat diet feeding, we confirmed in vivo the oxidized lipid
dependency of cardiac adipogenesis and right ventricle systolic
impairment, which are counteracted by atorvastatin treatment.
The modulatory role of oxidized lipids on ACM adipogenesis,
demonstrated at cellular, mouse, and patient levels, represents a
novel risk stratification tool and a target for ACM pharmacologi-
cal strategies.
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Introduction
Arrhythmogenic cardiomyopathy (ACM) is a heart condition with
genetic traits. It is hallmarked by a gradual fibro-adipose
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replacement of the ventricular myocardium, heart failure, malignant
arrhythmias, and sudden death (Basso et al, 2009).
ACM inheritance has mainly an autosomal dominant pattern and
most causative mutations reside in desmosomal genes, especially
PKP2 (Lazzarini et al, 2015). The reasons underpinning the charac-
teristic low penetrance and variable expressivity (Pinamonti et al,
2014) are still not properly understood. Genetic determinants and
environmental factors could play a role as phenotypic modulators
(Xu et al, 2010; König et al, 2017). For instance, physical exercise
worsens both ACM arrhythmic burden (La Gerche, 2015) and
myocardial dysfunction (Saberniak et al, 2014).
Disease severity markers must be improved, and only few phar-
macological approaches to counteract disease progression have been
proposed (Chelko et al, 2016; Chelko et al, 2019).
ACM electrical dysfunction is determined by genetically
impaired cardiomyocytes and worsened by adipose tissue pres-
ence (Samanta et al, 2016; De Coster et al, 2018), which we
showed to derive, at least partly, from differentiation of cardiac
mesenchymal stromal cells (C-MSCs; (Lombardi et al, 2016;
Sommariva et al, 2016; Stadiotti et al, 2017)). C-MSC, being
primary human cells directly obtained from patients ventricular
biopsy, easy to isolate and to amplify (Pilato et al, 2018), carrying
the whole patient’s genetic setting and recapitulating ACM adipo-
genesis in vitro (Sommariva et al, 2016), represent a valid cell
model to study ACM.
A key regulator of ACM adipogenesis is the proliferator-activated
receptor gamma (PPARc), whose activation is dependent on Wnt/
bcatenin- (Garcia-Gras et al, 2006) and Hippo-pathway (Chen et al,
2014) impairment. Accordingly, PPARc modulators rosiglitazone or
13-hydroxy-octadecadienoic acid (13HODE) have been used to shift
glycolysis to fatty acid metabolism to model ACM lipogenesis in
human induced pluripotent stem cell (hiPSC)-derived cardiomy-
ocytes (hiPSC-CM) (Kim et al, 2013). In other conditions such as
atherosclerosis, the involvement of oxidized low-density lipopro-
teins (oxLDL) and their component 13HODE in regulating cell lipid
accumulation is well known. In particular, after oxLDL cellular
internalization by scavenger receptors, such as CD36 (Sun et al,
2007), 13HODE directly induces PPARc expression (Tontonoz et al,
1998), provoking CD36 expression increase, thus facilitating addi-
tional oxLDL uptake and further PPARc activation in a feed-forward
circle (Jostarndt et al, 2004). Notably, 13HODE blood concentra-
tions have been used as an exercise-induced oxidative stress marker
in athletes (Powers & Jackson, 2008; Nieman et al, 2014; Sugama
et al, 2015).
An adjunctive clue hinting to a link between LDL levels and
cardiac adipocyte accumulation comes from available ACM-
transgenic mice, which fail to accumulate considerable amount of
myocardial fat (McCauley & Wehrens, 2009). In fact, mice, unlike
humans, show low circulating total cholesterol, which mostly
resides in HDL fractions (Kashyap et al, 1995).
We thus hypothesized that oxLDL/CD36/PPARc circuitry may
be a trigger of adipogenesis, and related clinical phenotypes, in
ACM. Through the investigation of ACM patient features, in vitro
experiments on patient-derived cardiac cells (both C-MSC and
hiPSC-CM) and in vivo studies with Pkp2 heterozygous knock-out
mice (Pkp2+/), we consistently showed for the first time
that oxLDL and elevated oxidative status contribute to ACM
phenotype severity.
Results
ACM patients show high plasma and cardiac lipid
peroxidation indices
We evaluated oxLDL and 13HODE plasma concentrations in ACM
patients and HC, matched for sex, age, and cardiovascular risk
factors (Appendix Table S1). As reported in Fig 1A, ACM patients
showed higher plasma oxLDL compared to HC (n = 36; ACM
137.90  20.85 vs. HC 66.74  5.79 ng/ml; P = 0.015). Accord-
ingly, plasma 13HODE was found significantly higher in patients
than controls (Appendix Table S1).
Interestingly, we observed a difference in oxLDL mean levels
between patients with overt ACM phenotype carrying ACM-related
causative mutations and their relatives, carriers of the same muta-
tions but not clinically affected by the pathology (n = 7 vs. n = 9;
ACM 384.50  139.1 vs. unaffected relatives 66.99  17.09 ng/ml;
P = 0.02; Fig 1B; Appendix Fig S1; Appendix Table S2). This
evidence points to an association between a fully penetrant disease
and high oxLDL plasma concentration.
In addition, we did not observe differences in oxLDL plasma
concentrations between patients with PKP2 mutations and patients
with mutations in other ACM-associated genes or gene elusive
(n = 12 vs. n = 22; Fig 1C; Appendix Table S3; Appendix Fig S2;
Appendix Table S5), indicating that oxLDL elevation is not linked
only to PKP2 forms.
To understand whether high plasma oxLDL and 13HODE have a
correspondence at cardiac tissue levels, we quantified the lipid
peroxidation marker MDA on ACM and control RV sections, finding
higher oxidative stress in ACM hearts (n = 4; MDA relative densito-
metric analysis (d.a.)/nuclei numbers ACM 36.25  10.43 vs. HC
1.00  0.72; P = 0.015; Fig 1D).
CD36 receptor has a central role in oxLDL uptake (Tontonoz
et al, 1998). CD36 immunostaining on RV tissue from ACM and HC
donors revealed higher CD36 expression in ACM samples (n = 4;
CD36 relative d.a./nuclei numbers ACM 14.72  2.10 vs. HC
1.00  0.40; P = 0.0007; Fig 1E), which was mainly distributed in
replacement tissue areas.
Elevated oxLDL plasma concentrations are associated with
structural and functional impairment and arrhythmic burden in
ACM patients
Since Fig 1B suggested a role of oxLDL in ACM phenotype worsen-
ing, we retrospectively investigated the association between plasma
oxLDL levels and structural, functional, and arrhythmic features in
our whole ACM patient cohort. A ROC curve analysis identified the
cut-off value of 86 ng/ml which best discriminates ACM patients vs.
HC (n = 36; 63.41% sensitivity and 65.85% specificity; Fig 2A).
Based on this cut-off value, we subdivided our ACM patient cohort
in two groups (n = 26 < 86 ng/ml oxLDL and n = 41 > 86 ng/ml
oxLDL). In the sub-cohort of ACM patients for which MRI was
performed in our hospital, we quantified the mass of ventricular fat
infiltration (Aquaro et al, 2014). Strikingly, patients with oxLDL
plasma concentrations above the cut-off showed significantly higher
myocardial fat infiltration (n = 14 vs. n = 25; fat infiltration mass
< oxLDL 2.27  1.35 vs. > oxLDL 15.32  4.62 grams; P = 0.04;
Fig 2B). Beside greater structural impairment, the group with higher
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oxLDL also showed a higher frequency of RV dysfunction defined as
in (Marcus et al, 2010) (n = 26 vs. n = 41; % of patients with RV
dysfunction < oxLDL 26.9% (7/26) vs. > oxLDL 53.7% (22/41);
P = 0.04; Fig 2C), biventricular dysfunction (n = 26 vs. n = 41; %
of patients with biventricular dysfunction < oxLDL 0% (0/26) vs.
> oxLDL 19.5% (8/41); P = 0.02; Fig 2D), and RV wall motion
abnormalities (n = 26 vs. n = 41; % RV wall motion abnormalities
< oxLDL 38.4% (19/26) vs. > oxLDL 70.7% (29/41); P = 0.01;
Fig 2E). Accordingly, RV EF was significantly reduced in patients
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50.71  2.40 vs. > oxLDL 44.5  1.72; P = 0.04; Fig 2F), con-
firming that higher oxLDL is associated with functional impairment.
Intriguingly, a Kaplan–Meier analysis revealed that ACM patient
survival free from major arrhythmic events (MAEs) over 5-year
follow-up was significantly higher in the subset of patients with low
amount of oxLDL (n = 67; log-rank P < 0.0001; hazard ratio = 0.223
[0.116–0.428]; mean follow-up 7.99  0.39 years; Fig 2G), demon-
strating the association between oxLDL levels and the occurrence of
MAE in ACM patients.
ACM C-MSC show elevated oxidative stress and PPARc and
CD36 expression
To model adipogenesis in vitro, we obtained ACM and HC C-MSC
from RV endomyocardial biopsies (Casella et al, 2020), as previ-
ously described (Pilato et al, 2018). To evaluate ACM C-MSC reac-
tive oxygen species (ROS), we performed a dichlorofluorescein
(DCF) test. As shown in Fig 3A, oxidative stress is significantly
higher in ACM C-MSC compared to HC C-MSC (n = 5; relative mean
DCF emission ACM 1.63  0.26 vs. HC 1.00  0.06; P = 0.049). At
least part of the ACM C-MSC oxidative stress resulted in lipid peroxi-
dation, as shown by MDA cell immunofluorescence (n = 4 vs.
n = 5; MDA relative d.a./nuclei number ACM 8.83  2.78 vs. HC
1.00  0.51; P = 0.017; Fig 3B). To understand whether excess
oxidative stress is due to a defect in antioxidant capacity, we
measured the ratio between reduced (GSH) and oxidized glutathione
levels in HC and ACM C-MSC, obtaining no differences between the
two groups (n = 8; Fig 3C).
In addition, ACM C-MSC in growth medium (GM) showed higher
PPARc and CD36 levels compared to HC (n = 18; PPARc/GAPDH
d.a. ACM 1.47  0.12 vs. HC 1.00  0.06; P = 0.002; n = 17 vs.
n = 16; CD36/GAPDH d.a. ACM 1.52  0.20 vs. HC 1.00  0.16;
P = 0.02; Fig 3D).
Lipid accumulation and CD36 levels increase in ACM C-MSC upon
adipogenic stimulus
Since corresponding transcription levels of CD36 and PPARc, as well
as lipid accumulation, are described for other cell types (Tontonoz
et al, 1998), we evaluated whether ACM C-MSC, already predis-
posed to PPARc activation (Sommariva et al, 2016), were more
prone to expose CD36 on the plasma membrane during lipid accu-
mulation. We performed a double staining with Nile Red, marking
neutral lipids, and anti-CD36 antibody in ACM and HC C-MSC,
cultured in adipogenic medium (AM) for different time-points (0, 3,
6, and 10 days). Figure 3E shows that, during adipogenic differenti-
ation, ACM C-MSC simultaneously increase CD36 and lipid content
significantly more than HC cells. In both ACM and HC cells, a linear
correlation is present between these two parameters (P = 0.008 and
0.03, respectively); however, a higher slope in ACM C-MSC was
evident (n = 4 vs. n = 5; ACM slope 1.33; R2 = 0.99 vs. HC slope
0.69; R2 = 0.93; slopes statistically different P = 0.016). To explore
CD36 activity during adipogenic differentiation, we evaluated C-
MSC oxLDL internalization, by assessing the intracellular fluores-
cence after 10 lg/ml DiI dye-conjugated oxLDL treatment (DiI-
oxLDL), either in GM or in AM. ACM C-MSC internalized more DiI-
oxLDL in AM compared to GM (n = 3; DiI internalization ACM GM
2.22  0.16 vs. ACM AM 6.29  0.65; P = 0.002) and 3-fold more
than controls in AM (P = 0.01; Fig 3F). Furthermore, lipidomic
assays confirmed ACM C-MSC transition toward an adipogenic
lineage (Appendix Fig S3).
OxLDL and 13HODE enhance lipid accumulation in ACM C-MSC
To test the hypothesis that oxLDL exacerbate adipogenic propensity
in ACM C-MSC through a vicious circle implicating CD36 and
PPARc, we treated ACM and HC C-MSC with or without 150 µg/µl
oxLDL in AM. The presence of oxLDL caused increased lipid accu-
mulation in ACM C-MSC compared to AM only (n = 11; ORO rela-
tive lipid accumulation ACM AM 6.19  0.83 vs. ACM AM+oxLDL
11.86  2.64; P = 0.01; Fig 4A), as well as CD36 and PPARc
expression (n = 5; PPARc/GAPDH d.a. ACM AM 1.52  0.13 vs.
ACM AM+oxLDL 2.78  0.44; P = 0.01; n = 5; CD36/GAPDH
d.a. ACM AM 1.18  0.61 vs. ACM AM+oxLDL 2.29  0.95;
P = 0.01; Fig 4A).
By mimicking PKP2 haploinsufficiency through a silencing
approach, we demonstrated that oxLDL susceptibility is dependent
on desmosomal protein defect (Appendix Fig S4).
To understand whether 13HODE is one of the determinants of
oxLDL-dependent adipogenesis in ACM, we cultured ACM and HC
C-MSC for 72 h in AM, with or without 20 lg/ml 13HODE. Impor-
tantly, 13HODE significantly increased lipogenesis in ACM C-MSC
only (n = 12; ORO relative lipid accumulation ACM AM 3.60  0.82
vs. ACM AM+13HODE 4.75  0.92; P = 0.048; Fig 4B). In the same
experiment, we obtained PPARc and CD36 level upregulation after
13HODE treatment in ACM C-MSC (n = 8; PPARc/GAPDH d.a. ACM
AM 1.67  0.16 vs. ACM AM+13HODE 2.17  0.20; P = 0.047;
n = 8; CD36/GAPDH d.a. ACM AM 1.22  0.06 vs. ACM
AM+13HODE 1.78  0.20; P = 0.008; Fig 4C), as expected in light
of the previously described mechanism (Jostarndt et al, 2004).
◀ Figure 1. ACM patients show high plasma oxLDL, cardiac lipid peroxidation, and oxLDL receptor levels.
A oxLDL plasma concentration in ACM patients and HC (n = 36; Mann–Whitney test).
B oxLDL plasma concentration in mutated ACM (n = 7) and non-ACM relatives, carriers of the same causative mutation (n = 9; Mann–Whitney test).
C oxLDL plasma concentration in ACM patients carriers of a PKP2 mutation and ACM patients carriers of other desmosomal or non desmosomal mutations, or gene
elusive (n = 10 vs. n = 26; one-way ANOVA).
D Representative images of MDA immunostaining (green) on ACM and HC ventricular tissue sections and relative quantification (n = 4 biological replicates; two-tailed
Student’s t-test). Nuclei are counterstained with Hoechst33342 (blue).
E Representative images of CD36 immunostaining (green) on ACM and HC ventricular tissue sections and relative quantification (n = 4 biological replicates; two-tailed
Student’s t-test). Nuclei are counterstained with Hoechst33342 (blue).
Data information: mean  SEM. *P < 0.05; **P < 0.01; and ***P < 0.001.
Source data are available online for this figure.
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The antioxidant compound NAC reduces lipid accumulation in
ACM C-MSC
In an attempt to prevent the effects of oxidized agents on lipid
droplet accumulation in ACM cells, we tested the effect of the
antioxidant NAC. 5 mmol/l NAC treatment was able to contain
13HODE-dependent lipid accumulation in ACM cells (n = 12; ORO
quantification ACM AM+13HODE 4.75  0.92 vs. ACM AM+NAC
2.38  0.61; P < 0.0001; ORO quantification ACM AM+13HODE
4.75  0.92 vs. ACM AM+13HODE+NAC 3.48  0.78; P = 0.02;
Fig 4B). Accordingly, both PPARc and CD36 protein levels were
reduced (n = 7; PPARc/GAPDH d.a. ACM AM+13HODE 2.17  0.20
vs. ACM AM+NAC 1.03  0.08; P < 0.0001; PPARc/GAPDH d.a.
ACM AM+13HODE 2.17  0.20 vs. ACM AM+13HODE+NAC
1.31  0.15; P = 0.0001; n = 8; CD36/GAPDH d.a. ACM
AM+13HODE 1.72  0.20 vs. ACM AM+NAC 0.95  0.10;
P < 0.0001; CD36/GAPDH d.a. ACM AM+13HODE 1.72  0.20 vs.
ACM AM+13HODE+NAC 0.86  0.15; P < 0.0001; Fig 4C).
Moreover, NAC addition to AM led to lipid accumulation reduction
in ACM C-MSC compared to AM alone, suggesting that oxidative stress
plays a role in the lipogenic process per se (n = 12; ORO quantification
ACM AM 3.60  0.82 vs. ACMAM+NAC 2.38  0.61; P = 0.03; n = 7;
PPARc/GAPDH d.a. ACM AM 1.67  0.16 vs. ACM AM+NAC
1.03  0.08; P = 0.007; Fig 4B and C). The effect is possibly due to a
direct action of NAC on gene expression as previously described in
macrophages during foam cell formation (Sung et al, 2012).
A
C D E F G
B
Figure 2. Plasma oxLDL cut-off value of 86 ng/ml defines two patient subpopulations with different severity of ACM phenotypes.
A ROC curve shows the capability of plasma oxLDL concentration in discriminating ACM vs. HC subjects (data as in Fig 1A). The red dot shows the point where the
difference between sensitivity and specificity is minimized; this value, corresponding to the oxLDL cut-off = 86 ng/ml, was used to part the whole ACM cohort in two
subpopulations.
B Left panels: representative images of three cases of ACM in steady-state free procession sequences at cardiac MRI. On the left, a case with RV dilation, regional
bulging of the RV wall without fat infiltration, and oxLDL levels below the cut-off; in the center and on the right, two cases with fat infiltration in the right or left
ventricle wall (white arrow), respectively, and oxLDL levels above the cut-off. Right panel: quantification of the myocardial fat mass of the two ACM subpopulations
(above or below the cut-off) whose MRI was available for re-analysis (n = 14 oxLDL < 86 ng/ml, n = 25 oxLDL > 86 ng/ml; two-tailed Student’s t-test).
C Frequency of patients showing RV dysfunction (defined as in (31)) in the two ACM cohort subgroups (n = 26 oxLDL < 86 ng/ml vs. n = 41 oxLDL > 86 ng/ml; two-
tailed Student’s t-test).
D Frequency of patients showing biventricular dysfunction in the two ACM cohort subgroups (n = 26 oxLDL < 86 ng/ml vs. n = 41 oxLDL > 86 ng/ml; two-tailed
Student’s t-test).
E Frequency of patients showing RV wall motion abnormalities in the two ACM cohort subgroups (n = 26 oxLDL < 86 ng/ml vs. n = 41 oxLDL > 86 ng/ml; Fisher’s
exact test).
F RV ejection fraction % of the patients classified in the two ACM cohort subgroups (n = 23 oxLDL < 86 ng/ml vs. n = 39 oxLDL > 86 ng/ml; two-tailed Student’s t-test).
G Kaplan–Meier analysis of actual MAE-free survival of patient belonging to the two ACM cohort subgroups in the first 5-year follow-up (n = 26 oxLDL < 86 ng/ml vs.
n = 41 oxLDL > 86 ng/ml; log-rank P < 0.0001; HR = 0.223[0.116–0.428]).
Data information: mean  SEM. *P < 0.05.
Source data are available online for this figure.
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CD36 silencing and PPARc inhibition in ACM C-MSC impair the
lipid accumulation mechanism
To directly assess CD36 causal role in ACM cell adipogenic process,
we performed CD36 siRNA-mediated silencing in AM supplemented
with oxLDL. 32% mean reduction in CD36 levels (n = 7; P = 0.014;
Fig 5A) in ACM C-MSC was enough for inducing significantly less
lipid accumulation if compared to the non-silenced counterparts
(n = 7; ORO relative lipid accumulation scramble 1.00  0.19 vs.
siRNA 0.35  0.10; P = 0.003; Fig 5B), along with PPARc reduced
levels (n = 7; PPARc/GAPDH relative d.a. scramble 1.00  0.18 vs.
siRNA 0.76  0.15; P = 0.05; Fig 5A). In addition, CD36 levels
(both with and without silencing) correlated with PPARc (n = 14;
slope=1.05; R2 = 0.76; P = 0.0002) and to a lesser extent with
ORO staining (n = 14; slope=0.52; R2 = 0.26; P = 0.07; Fig 5C).




Figure 3. ACM C-MSC show elevated oxidative stress, PPARc, and CD36 expression, and, during adipogenic differentiation, CD36 levels and functionality.
A Left panel: exemplificative FACS analysis of the FITC emission of unstained HC C-MSC (autofluorescence; white), HC C-MSC in GM treated with DCF (gray), ACM C-
MSC in GM treated with DCF (red), and HC cells in GM treated with 2 mmol/l H2O2 as positive control (blue). Right panel: mean DCF emission of HC and ACM C-MSC
in GM (n = 5 biological replicates; two-tailed Student’s t-test).
B Left panels: representative images of MDA immunostaining (green) on ACM and HC C-MSC in GM. Nuclei are counterstained with Hoechst33342 (blue). Right panel:
image quantification (n = 4 biological replicates ACM, n = 5 biological replicates HC; two-tailed Student’s t-test).
C GSH/GSSG ratio quantification in HC and ACM C-MSC cultured in GM (n = 8 biological replicates).
D Top panel: representative images of Western blot analysis of proteins extracted from ACM and HC C-MSC cultured in GM, hybridized with anti-CD36 and anti-PPARc
antibodies. Immunostaining of the housekeeping GAPDH is shown for normalization. Bottom panel: d.a. of PPARc (n = 18 biological replicates) and CD36 (n = 17 vs.
n = 16 biological replicates) levels, normalized on GAPDH (Mann–Whitney test).
E Results of a FACS analysis of ACM and HC C-MSC, cultured in GM (time-point 0) or AM for 3, 6 or 10 days (time-points 3, 6,and 10, respectively) and marked with
anti-CD36 antibody and Nile red. The mean (n = 4 biological replicates ACM, n = 5 biological replicates HC) fluorescence of CD36 and Nile Red is shown for each
condition, the relative regression line, its equation, R2, and P-value (X-Y correlation).
F Top panels: representative images of internalization of oxLDL (red) in HC and ACM cells, cultured either in GM or in AM, and subjected to 10 lg/ml DiI-oxLDL
treatment. Nuclei are counterstained with Hoechst33342 (blue). Bottom panel: quantification of the relative mean DiI fluorescence for each sample, measured by
FACS analysis (n = 3 biological replicates; two-way ANOVA).
Data information: mean  SEM. *P < 0.05 and **P < 0.01.
Source data are available online for this figure.
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internalization (n = 3; DiI internalization scramble 7.34  1.31 vs.
siRNA 0.63  0.13; P = 0.04; Fig 5D).
oxLDL/CD36/PPARc interdependence in ACM cells was also con-
firmed by inhibiting PPARc with the antagonist GW9662. This
provoked a significant reduction of oxLDL internalization (n = 3;
DiI internalization ACM AM 25,137  3,567 vs. ACM AM+GW9662
10,194  3,787; P = 0.01; Fig 5E), together with a lower expression
of CD36 (n = 3; CD36/GAPDH d.a. ACM AM 1.26  0.08 vs. ACM
AM+GW9662 0.97  0.14; P = 0.04; Fig 5F).
In addition, we confirmed that lipid accumulation and CD36
levels and functionality increased also in human ACM cardiomy-
ocytes (using hiPSC-CM derived from ACM patients vs. unaffected
relatives) upon PPARc agonism (Appendix Fig S5).
HFD administration leads to cardiac lipid accumulation and
dysfunction in Pkp2+/ mice
To validate our hypothesis on an ACM in vivo model, we took
advantage of the well-established Pkp2+/ mouse (Grossmann
et al, 2004; Sato et al, 2009). Despite adult Pkp2+/ mice showed
no cardiac adipogenesis, low oxidative stress and CD36 levels, and
no cardiac dysfunction, C-MSC obtained from the mutant mice accu-
mulated lipids in vitro (Appendix Figs S6 and S7).
We thus fed Pkp2+/ mice a HFD for 3 months to test the
hypothesis that increasing cholesterol and oxidative stress levels





Figure 4. ACM C-MSC lipogenesis is increased with oxLDL or 13HODE and prevented by NAC treatment.
A Left panels: representative images of ORO staining on ACM and HC C-MSC in AM supplemented or not with 150 µg/ml oxLDL. Middle panel: image quantification
(n = 11 biological replicates; two-way ANOVA). Right panels: representative images of Western blot of CD36, PPARc, and GAPDH protein expression of ACM and HC C-
MSC protein extracts in AM supplemented or not with 150 µg/ml oxLDL (n = 5 biological replicates) and d.a. normalized on the housekeeping GAPDH (two-way
ANOVA).
B Left panels: representative images of ORO staining on ACM and HC C-MSC in AM supplemented or not with 20 lg/ml 13HODE, 5 mmol/l NAC, or both. Right panel:
image quantification (n = 13 biological replicates; two-way ANOVA).
C Left panel: representative images of Western blot of CD36, PPARc, and GAPDH protein expression of ACM and HC C-MSC protein extracts in AM supplemented or not
with 20 lg/ml 13HODE, 5 mmol/l NAC, or both (n = 8 biological replicates). Right panels: d.a. normalized on the housekeeping GAPDH (two-way ANOVA).
Data information: mean  SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
Source data are available online for this figure.
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In both strains, plasma total cholesterol concentrations in the
lipoprotein fractions comparably increased after HFD. In particular,
higher cholesterol was measured in HFD in fractions 29–32, repre-
senting VLDL-IDL-LDL (n = 8; P < 0.0001 each fraction; Fig 6A). Of
note, HFD also increased oxLDL (n = 6; oxLDL nmol/ml HFD
1.29  0.11 vs. CD 0.83  0.05; P = 0.049; Fig 6B).
Following HFD, cardiac sections from Pkp2+/ mice showed
larger areas of fatty substitution compared to WT siblings (n = 10;
% ORO positive area Pkp2+/ 1.04  0.24 vs. WT 0.13  0.02;
P < 0.0001; Fig 6C), prevalently in sub-epicardial areas. As
expected, the cells undergoing adipogenic differentiation in murine
hearts are of mesenchymal origin (Appendix Fig S8). Accordingly,
the difference in PPARc immunoreactivity between WT and Pkp2+/
hearts substantially increased with HFD (n = 10; PPARc d.a./nuclei
number Pkp2+/ 8.66  1.59 vs. WT 2.13  0.79; P = 0.0001;
Fig 6D; Appendix Fig S9).
Pkp2+/ mouse hearts also showed oxidative stress (n = 10;
MDA relative d.a./nuclei number Pkp2+/ 10.43  2.19 vs. WT
1.71  1.21; P = 0.0003; Fig 6E; Appendix Fig S8) and CD36 level
increase (n = 10; CD36 relative d.a./nuclei number Pkp2+/
7.11  1.72 vs. WT 2.99  0.68; P = 0.04; Fig 6F; Appendix Fig
S8). Moreover, HFD induced RV dysfunction but no changes in LV
function, as assessed by 2D echocardiography. In particular, ACM
mice after 3 months of diet presented a lower RV ejection fraction
(EF), fractional shortening (FS), and RV internal diameter (RVID)
in systole compared to WT (n = 10; %RV EF Pkp2+/
73.44  3.17 vs. WT 82.66  1.36; P = 0.02; %RV FS Pkp2+/
40.11  2.74 vs. WT 48.14  1.55; P = 0.02; RVID systole
Pkp2+/ 0.93  0.05 vs. WT 0.75  0.05 mm; P = 0.03; Fig 6G).
Morphometric analyses are shown in Appendix Fig S10. Accord-
ingly, mouse electric activity resulted impaired by the combination







Figure 5. CD36 silencing reduces lipid accumulation and PPARc antagonism reduces CD36 expression and function in ACM C-MSC.
A Left panel: representative images of Western blot of CD36, PPARc, and GAPDH expression of protein extracts of ACM C-MSC treated with scramble siRNA or CD36
siRNA. Right panels: d.a. normalized on the housekeeping protein GAPDH (n = 7 biological replicates; two-tailed Student’s t-test).
B Left panels: representative images of ORO staining on ACM C-MSC treated with scramble siRNA or CD36 siRNA and cultured in AM with 150 µg/ml oxLDL. Right
panel: image quantification (n = 7 biological replicates; two-tailed Student’s t-test).
C Left panel: correlation between CD36/GAPDH and PPARc/GAPDH d.a. Right panel: correlation between CD36/GAPDH d.a. and ORO lipid accumulation. Regression lines,
their equations, R2, and correlation P values are shown (X-Y correlation).
D Left panel: representative images of internalization of oxLDL (red) in ACM C-MSC treated with scramble siRNA or CD36 siRNA, cultured in AM and subjected to 10 lg/
ml DiI-oxLDL treatment. Right panel: quantification of the DiI fluorescence normalized on nuclei number (n = 3 biological replicates, arbitrary units; two-tailed
Student’s t-test).
E Left panel: representative images of internalization of oxLDL (red) in ACM C-MSC cultured in AM or AM+5 lM GW9662 and subjected to 10 lg/ml DiI-oxLDL
treatment. Nuclei are counterstained with Hoechst33342 (blue). Right panel: quantification of the DiI fluorescence normalized on nuclei number for each sample
(n = 3 biological replicates, arbitrary units; two-tailed Student’s t-test).
F Left panel: representative images of Western blot of CD36 and GAPDH expression of protein extracts of ACM C-MSC cultured in AM or AM+5 lM GW9662. Right
panels: d.a. normalized on the housekeeping GAPDH (n = 7 biological replicates; two-tailed Student’s t-test).
Data information: mean  SEM. *P < 0.05 and **P < 0.01.
Source data are available online for this figure.
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(ECG) trace change and CX43 reduction and mislocalization
(Appendix Fig S11).
Atorvastatin administration prevents ACM manifestation in
HFD-fed Pkp2+/ mice
To evaluate the effect of the pharmacological counteraction of high
oxLDL levels (Tsimikas et al, 2004), we fed WT and Pkp2+/ mice
a 3-month HFD supplemented with 20 mg/kg atorvastatin. In both
strains, lower cholesterol was measured in HFD+atorvastatin in
fractions 29–32, representing VLDL-IDL-LDL (n = 8; P < 0.001;
Fig 7A). Moreover, in parallel with plasma oxLDL concentration
reduction (n = 6 vs. n = 8; oxLDL nmol/ml HFD 1.29  0.11 vs.
HFD+atorva 0.56  0.05; P = 0.009; Fig 7B), we observed lower
cardiac lipid accumulation (n = 10 vs. n = 9; %ORO+ area
Pkp2+/ HFD 1.04  0.24 vs. Pkp2+/ HFD+atorva 0.02  0.001;
P = 0.001; Fig 7C) and a dramatic decrease of PPARc expression
levels (n = 10 vs. n = 9; PPARc d.a./nuclei number Pkp2+/ HFD
8.65  1.59 vs. Pkp2+/ HFD+atorva 0.02  0.006; P < 0.0001;
Fig 7D; Appendix Fig S9). MDA expression also significantly
decreased (n = 10 vs. n = 9; MDA relative d.a./nuclei number
Pkp2+/ HFD 10.43  2.19 vs. Pkp2+/ HFD+atorva
0.02  0.007; P = 0.0003; Fig 7E; Appendix Fig S9) as well as
CD36 levels (n = 10 vs. n = 9; CD36 relative d.a./nuclei number
Pkp2+/ HFD 7.11  1.72 vs. Pkp2+/ HFD+atorva 0.03  0.01;
P = 0.001; Fig 7F; Appendix Fig S9). Moreover, RV EF, RV FS, and
RVID in systole improved in Pkp2+/ HFD+atorva with respect to
HFD only (n = 10 vs. n = 9; %RV EF Pkp2+/ HFD 73.44  3.17
vs. Pkp2+/ HFD+atorva 82.14  1.74; P = 0.04; %RV FS
Pkp2+/ HFD 40.11  2.74 vs. Pkp2+/ HFD+atorva
47.94  2.01; P = 0.04; Fig 7G). Defects in the ECG were prevented
by atorvastatin treatment, as well as those in CX43 expression and
localization (Appendix Fig S12).
Discussion
Current information about ACM genetic basis does not fully explain
reduced penetrance and phenotypic variability (Pinamonti et al,
2014). Among ACM pathogenic pathways, metabolic dysfunctions
are thought to play a relevant role, given the well-established
involvement of PPARc and recent discoveries on the topic (van
Opbergen et al, 2019; Song et al, 2020).
In the present study, we defined the contribution of oxLDL/
CD36/PPARc circuitry as ACM penetrance cofactor, demonstrating,
for the first time, that oxidative stress and oxidized lipid metabolism
modulate ACM adipogenic phenotype, both in vitro and in vivo.
Interestingly, such biological axis is pharmacologically targetable in
order to reduce the adipogenic phenotype and consequent disease
severity in ACM.
This hypothesis-driven study was prompted by the observations
in ACM patient plasma of higher oxLDL and 13HODE plasma levels
as compared to matched HC. Our cohort was composed of 81%
male and 38% athletic patients. Of note, strenuous exercise and
male sex are the only accepted cofactors precipitating ACM pheno-
type. The association of both exercise and male gender with oxida-
tive stress is well known (Miller et al, 2007). Oxidative stress can
induce oxidation of different proteins and complexes, including LDL
(Sanchez-Quesada et al, 1995).
Our data suggest that a higher oxLDL concentration in ACM
patient plasma is not a mere consequence of the causative genetic
defect. Indeed, we observed that oxLDL plasma levels are higher in
ACM patients than in their unaffected relatives, carriers of the same
ACM causative genetic mutation. Further, oxLDL elevation is not
linked to a specific genetic form of ACM, even if, given the low
prevalence in our cohort of carriers of pathogenic mutations in
desmosomal genes other than PKP2, testing each single gene associ-
ation was not possible. On the other hand, we identified background
variants in genes associated with oxidative stress or dyslipidemia
co-segregating with the ACM phenotype (Appendix Fig S1;
Appendix Table S4; Dataset EV1). These results will need confirma-
tion in larger cohorts. Other factors, including lifestyle and diet, or
unidentified protective genetic variants, may play a role in modulat-
ing oxLDL concentrations.
Notably, we unraveled in our ACM patients a strong association
between oxLDL plasma levels above the cut-off of 86 ng/ml and
pathognomonic ACM structural and clinical features. Such circulat-
ing oxLDL cut-off allowed to segregate ACM patient population with
a severe clinical phenotype in terms of fat infiltration, ventricular
dysfunction, and risk of major arrhythmic events in the long term.
In addition, these data are relevant to confirm oxLDL pathogenic
role at a clinical level and to introduce oxLDL plasma levels as new
◀ Figure 6. HFD increases plasma oxLDL, cardiac adipose substitution, PPARc and CD36 expression, and lipid peroxidation, and impairs RV function in ACMmice.
A Left panel: plasma total cholesterol in the different lipoprotein fractions of WT and Pkp2+/ mice fed a CD (green line) or a 3-month HFD (blue line; n = 7). Right
panel: plasma total cholesterol quantity in fractions 29–32, corresponding to low-, very-low-, and intermediate-density lipoproteins, of WT and Pkp2+/ mice fed a
CD (green line) or a 3-month HFD (blue line; n = 7; Mann–Whitney test).
B Plasma concentration of oxLDL in WT and Pkp2+/ mice samples, fed a CD and a 3-month HFD (n = 6; two-tailed Student’s t-test).
C Left panels: representative images of ORO staining of HFD-fed WT and Pkp2+/ cardiac sections. Right panel: quantification of ORO positive area percentage
(n = 10). For comparison, quantification of ORO positive area of cardiac sections of CD-fed WT and Pkp2+/ mice (n = 9; two-way ANOVA) is shown
(Appendix Fig S3).
D Representative images of PPARc (green) immunostaining on HFD-fed WT and Pkp2+/ mice cardiac sections (n = 10; two-way ANOVA). Quantification of the PPARc
staining in HFD is shown relative to the values of CD (n = 9).
E Representative images of MDA (green) immunostaining on HFD-fed WT and Pkp2+/ mice cardiac sections (n = 10; two-way ANOVA). Quantification of the MDA
staining in HFD is shown relative to the values of CD (n = 9).
F Representative images of CD36 immunostaining (green) on HFD-fed WT and Pkp2+/ mice cardiac sections (n = 10; two-way ANOVA). Nuclei are counterstained
with Hoechst33342 (blue). Quantification of the staining in HFD is shown relative to the values of CD (n = 9).
G RV EF and FS percentages, RVID in systole and diastole of WT and Pkp2+/ mice after (right) 3-month HFD feeding (n = 10; two-tailed Student’s t-test).
Data information: mean  SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
Source data are available online for this figure.
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potential circulating prognostic marker in ACM (Stadiotti et al,
2018).
We used human C-MSC obtained from ACM heart biopsies and
HC as in vitro model, as they subsidize ACM-driven cardiac adipo-
genesis and represent a reliable cell model to study pathogenic
mechanisms (Sommariva et al, 2016; Sommariva et al, 2017). As
previously demonstrated in other cell models (Garcia-Gras et al,
2006; Chen et al, 2014; Sommariva et al, 2017), in ACM C-MSC we
found a higher expression of PPARc. In agreement with the oxLDL
receptor CD36 interdependence with PPARc, described in cardiovas-
cular atherogenic conditions (Nicholson et al, 1995), we found also
in ACM C-MSC a linear correlation between the activation of PPARc,
with consequent lipid accumulation, and CD36 expression and func-
tion. The proposed mechanism was confirmed by CD36 silencing,
which entailed a significant reduction of lipid accumulation in ACM
C-MSC, as well as by PPARc inhibition, which caused a reduction of
CD36 expression and function. Moreover, we described, for the first
time, that increased oxidative stress is present in ACM C-MSC, with-
out changes in their antioxidant capability. Thus, an analysis of
mitochondrial dysfunction as a source of oxidative stress is awaited
(van Opbergen et al, 2019).
We further demonstrated that oxLDL enhances C-MSC adipo-
genic differentiation. Accordingly, Parhami et al (1999) have previ-
ously shown that oxLDL promotes adipogenic differentiation of
bone marrow-derived MSC. We showed that 13HODE prompts, in
ACM patient C-MSC, a PPARc/CD36-dependent adipogenesis as an
intrinsic ACM pathogenic mechanism. 13HODE effect was previ-
ously used in ACM hiPSC-CM as a mere in vitro supplement to acti-
vate PPARc (Kim et al, 2013). Our results do not exclude that the
Wnt/bcatenin pathway may exert a modulatory role in the balance
of PPARc activation. In addition, we showed that PPARc-agonism
induces CD36 increased expression and function in ACM hiPSC-CM.
Importantly, cell exposure to the antioxidant NAC not only
prevented 13HODE-dependent lipogenesis and CD36/PPARc expres-
sion, but ameliorated C-MSC phenotype, possibly by reducing the
effects of basal oxidized lipids in their ability to activate PPARc, as
well as directly acting on the transcriptional profile of the cells, includ-
ing CD36 and PPARc expression (Ji et al, 2011; Sung et al, 2012).
We confirmed in vitro findings with in vivo experiments by
means of the Pkp2+/ mouse model (Grossmann et al, 2004),
since PKP2 heterozygous mutations are the most frequent in ACM
patients. Notably, available ACM in vivo models, including the
Pkp2+/ mouse, do not fully recapitulate the disease phenotype,
showing from absence to small amount of ventricular fibro-fatty
substitution, possibly due to an intrinsic protective mechanism.
Since it is known that mice show low cholesterol plasma levels,
we demonstrated that a consistent increase of plasma LDL choles-
terol, including the oxidized form, achieved by HFD feeding,
provoked fat accumulation in ACM mouse hearts. This phenom-
enon, borne by C-MSC, as previously proven in humans (Som-
mariva et al, 2016), was prevalently located in sub-epicardial
regions, in line with the epicardial-endocardial gradient observed
in ACM human hearts. In accordance with in vitro and patient
ex vivo results, cardiac oxidative stress and CD36 significantly
increased in ACM mouse hearts following HFD. Importantly, HFD
treatment provoked an initial impairment of RV function, in line
with the concept that myocardial substrate alterations lead to func-
tional impairment (Pabon et al, 2018; te Riele et al, 2014) and
adipocyte-secreted factors negatively influence CM contractility
(Lamounier-Zepter et al, 2009; Gastaldelli et al, 2012; Lamounier-
Zepter et al, 2014; Pabon et al, 2018). In addition, proarrhythmic
(Peters et al, 2012; Canpolat et al, 2013) ECG changes were
detected in the Pkp2+/ mice fed HFD. These results confirmed
that ACM causative mutations are necessary but not sufficient to
generate an overt ACM phenotype in mice, which was instead
obtained when increasing oxLDL levels, thus recognizing in oxLDL
a likely contributory pathogenic cause.
We cannot exclude that disease progression itself may, in turn,
further increase oxLDL levels in patients, e.g., by boosting ROS
production, inflammation, or other mechanisms. However, our
in vitro, in vivo, and clinical data clearly showed that maintaining
the levels of oxLDL low is beneficial in terms of disease progression.
Remarkably, atorvastatin administration prevented cardiac fat
accumulation and RV dysfunction in HFD-fed Pkp2+/ mice.
Beyond the described canonical lipid-lowering effects, we infer that
known pleiotropic effects, as anti-inflammatory (Antonopoulos
et al, 2012), DKK- and Wnt pathway- mediated (Pontremoli et al,
2018), as well as sympathetic activity reducing (Lewandowski et al,
2015), and antiarrhythmic (Kostapanos et al, 2007), may contribute
to ameliorate ACM cardiac phenotype.
◀ Figure 7. Atorvastatin prevented ACM phenotype in HFD-fed Pkp2+/ mice.
A Left panel: plasma total cholesterol in the different lipoprotein fractions of WT and Pkp2+/ mice fed a 3-month HFD (blue line) or a 3-month HFD+atorvastatin (red
line). Right panel: plasma total cholesterol quantity in fractions 29–32, corresponding to low-, very-low-, and intermediate-density lipoproteins, of WT and Pkp2+/
mice fed a 3-month HFD (blue line; n = 7) or a 3-month HFD+atorvastatin (red line; n = 9; two-tailed Student’s t-test).
B oxLDL plasma concentration in WT and Pkp2+/ mouse samples, fed a 3-month HFD plus atorvastatin (n = 8), compared to HFD (as in Fig 6B; two-tailed
Student’s t-test).
C Left panel: representative images of ORO staining of cardiac sections of Pkp2+/ mice, fed a 3-month HFD plus atorvastatin. Right panel: quantification of the
percentage of ORO positive area (n = 9) is compared to that in HFD (as in Fig 6C; two-tailed Student’s t-test).
D Representative images of PPARc immunostaining (green) on cardiac sections of Pkp2+/ mice fed a 3-month HFD plus atorvastatin (n = 9). Quantification is
compared to the values of Pkp2+/ in HFD and relative to WT in CD (as in Fig 6D; two-tailed Student’s t-test).
E Representative images of MDA immunostaining (green) on cardiac sections of Pkp2+/ mice fed a 3-month HFD plus atorvastatin (n = 9). Quantification is compared
to the values of Pkp2+/ in HFD and relative to WT in CD (as in Fig 6E; two-tailed Student’s t-test).
F Representative images of CD36 immunostaining (green) on cardiac sections of Pkp2+/ mice fed a 3-month HFD plus atorvastatin (n = 9). Quantification is compared
to the values of Pkp2+/ HFD and relative to WT in CD (as in Fig 6F; two-tailed Student’s t-test). Nuclei are counterstained with Hoechst33342 (blue).
G RV EF and FS percentages, RVID in systole and diastole of Pkp2+/ mice during (left panel) and after (right panel) 3-month HFD plus atorvastatin feeding (n = 9). For
comparison, RV EF of Pkp2+/ mice fed a HFD is shown (as in Fig 6G; two-tailed Student’s t-test).
Data information: mean  SEM. *P < 0.05; **P < 0.01; and ***P < 0.001.
Source data are available online for this figure.
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An interesting side-product of this project was the generation of
a novel diet-driven ACM mouse model showing fat accumulation
and RV dysfunction, thus better recapitulating, beyond arrhythmias
(Cerrone et al, 2012), human ACM substrate myocardial phenotype.
In conclusion, by means of a multilayer approach, we demon-
strated, for the first time, that oxidative stress increases oxLDL
bioavailability, which are internalized in C-MSC by CD36 receptor,
thus acting, through 13HODE-mediated PPARc activation, as a
cofactor of cardiac adipogenic differentiation and with dependent
phenotypes (Synopsis figure), which can be targeted by available
therapies such as antioxidants (Shafiei et al, 2018) or statins (Ky
et al, 2008). According to our findings, these strategies have the
potential to reduce the penetrance of the disease in ACM mutation
carriers, by attenuating cardiac adipose substitution, ventricular
dysfunction, and arrhythmic phenotypes.
Materials and Methods
Ethics statement
This study complies with the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report. It was
approved by “IEO-CCM IRCCS” (12/06/2012) and by "South Tyrol
Azienda Sanitaria" (13/03/2014, No. 1/2014) Ethics Committees.
Written informed consent was obtained from all participants. HC
cardiac samples were obtained from donors (accidental death), from
“Treviso Tissue Bank Foundation”.
Study patient population
A total of 67 ACM patients were enrolled for this study. ACM diag-
nosis was reached according to the 2010 International Task Force
criteria (Marcus et al, 2010). Thirty-six patients out of the total
cohort were matched for age, sex, and cardiovascular risk factors to
36 HC without a previous history of heart disease for plasma analy-
sis (Appendix Table S1 summarizes baseline characteristics of 36
ACM patients and 36 HC, and Appendix Table S3 describes the
genetic profile of ACM patients). We further enrolled for the plasma
analysis nine ACM patients’ relatives with PKP2 mutations but no
clinical signs of the disease.
We obtained blood samples from all the recruited ACM patients
and HC. ACM patients and HC taking statins or other lipid-lowering
drugs were excluded from the analysis. Clinical data were collected
for all ACM patients, as available: RV EF % was determined by
MRI; RV dysfunction was defined as in Li and Durbin (2010); and
MAEs are defined as sustained ventricular tachycardia, ventricular
fibrillation, appropriate implantable cardioverter device interven-
tion, and aborted sudden cardiac death. Genetic data on ACM-
linked genes were obtained for 65 out of 67 patients
(Appendix Table S5).
RV samples were obtained by biopsy procedures from 19 ACM
patients.
Plasma preparation
Blood samples (5 ml) were collected in EDTA-coated tubes and
centrifuged at 1,500 g for 15 min. Supernatants were collected,
centrifuged again at 16,000 g for 15 min to obtain cell- and platelet-
free plasma, and stored at 80°C as 400 µl aliquots until usage.
oxLDL in human plasma samples
Plasma samples from ACM patients and HC were used for the deter-
mination of oxLDL quantity, using a specific ELISA kit (Immundiag-
nostik, Bensheim, Germany). The test recognizes MDA-modified
apolipoprotein B100. The protocol recommended by manufacturers
was observed, and the absorption was determined with a spec-
trophotometer (Berthold Technologies, Bad Wildbad, Germany) at
450 nm. Results were interpreted by constructing a dose/response
curve according to the standards provided in the kit.
Genetic analysis
ACM-associated genes
DNA was extracted from blood or C-MSC using QIAamp DNA Mini
kit (Qiagen, Hilden, Germany). Next-generation sequencing was
performed with the TruSightTM Cardio Sequencing Kit (Illumina
NextSeq, San Diego, CA, USA). The alignment of sequence reads to
reference human genome (GRCh37/hg19) was performed using
GATK software. Variants in DSC2, DSG2, DSP, PKP2, JUP, TMEM43,
DES, RYR2, PLN, SCN5A, and LMNA were filtered with Wannovar
and pathogenicity classified according to Richards et al (2015).
Exome sequencing
NA samples from blood were prepared following the Nextera
Rapid Capture Exome Enrichment kit protocol. Libraries for all
samples, except Fam3.I.3, Fam3.I.4, and Fam3.II.3 (Appendix Fig
S1), were sequenced on two lanes of an Illumina HiSeq in paired-
end mode and a read length of 100 bp. The remaining three samples
were sequenced subsequently on four lanes of an Illumina MiSeq in
paired-end mode and a read length of 75 bp. Nextera adapters were
trimmed off using SeqPrep (https://github.com/jstjohn/SeqPrep),
and read quality was controlled with FastQC (http://www.bioinf
ormatics.babraham.ac.uk/projects/fastqc/). Reads were aligned
to reference genome GRCh37 with BWA version 0.7.15 (DePristo
et al, 2011). Duplicate marking was performed with picard tools
version 2.8.1 (https://broadinstitute.github.io/picard/). Indels were
realigned and base quality scores recalibrated using GATK 3.7 (Van
der Auwera et al, 2013), following the GATK best practice guideli-
nes (Van der Auwera et al, 2013). Quality of bam files was evalu-
ated with QualiMap version 2.2.1 (Garcia-Alcalde et al, 2012),
sample contamination estimated with verifyBamId (Jun et al, 2012),
and sex validated by inspection of the X chromosome coverage.
Intermediate per sample gvcfs were generated with the GATK
HaplotypeCaller, followed by joint genotyping on all individuals
with GATK GenotypeGVCFs and additional samples not related to
this study. Variants were called on the exonic target regions
as defined by the Nextera protocol with a padding of 100 bp
around the exons. Variants were annotated with Ensembl gene and
variant consequence data using the Dintor gcoords2cons tool
(Weichenberger et al, 2015). For each variant, the annotation of the
transcript with the worst consequence type as according to Ensembl
was selected.
First, using the Dintor MendelianFiltration tool, variants were
selected that were present either in homo- or heterozygous form in
ª 2021 The Authors EMBO Molecular Medicine 13: e14365 | 2021 13 of 23
Elena Sommariva et al EMBO Molecular Medicine
all affected individuals of all three families, requiring a coverage of
at least 10X at variant sites in the respective individuals. Variants
were restricted to those mapped to a gene of the oxidative
stress and dyslipidemia gene panel (Dataset EV1). Further, variants
were removed, if their ExAC EUR allele frequency (AF) (Lek et al,
2016), their gnomAD NEF AF (Lek et al, 2016), or their 1,000
Genomes phase 3 EUR AF (Auton et al, 2015) was greater than 0.3.
Variants were not required to be in protein-coding genes
(Appendix Table S4A).
Next, each family was analyzed individually. Using the Dintor
MendelianFiltration tool, variants were selected that were present in
a families’ affected PKP2 carriers, but absent in the same families’
healthy PKP2 carriers, requiring a coverage of at least 10X at the
variant sites in the relevant individuals. For the selection, variants
segregating in the affected PKP2 carriers in either a dominant or a
recessive mode of inheritance were accepted. Variants were
restricted to those mapped to a gene of the oxidative stress and
dyslipidemia gene panel (Dataset EV1). Further, variants were
removed, if their ExAC EUR allele frequency (AF) (Lek et al,
2016), their gnomAD NEF AF (Lek et al, 2016), or their 1,000
Genomes phase 3 EUR AF (Auton et al, 2015) was greater than
0.05. Variants were not required to be in protein-coding genes
(Appendix Table S4B).
Per sample, an average of 55 million17 million reads mapped
to reference genome, resulting in a mean coverage of 57X21X, and
87%4% of the exon target region covered at ≥ 10X. The sex of all
samples was confirmed by inspection of the coverage of the X chro-
mosome, and sample contamination was below 1%.
13HODE quantification
The determination of plasma 13HODE levels was performed by a
liquid chromatography–tandem mass spectrometry (LC-MS/MS)
method. Briefly, plasma samples (100 µl) were acidified with 1%
formic acid, mixed with the internal standard (d4-13HODE, final
concentration 50 pg/µl; Cayman Chemicals, Ann Arbor, Michigan,
USA), and purified through HLB extraction cartridges (Oasis HLB
1cc (30 mg), Waters, Milford, Massachusetts, USA). The eluted
fraction was evaporated to dryness and reconstituted with 250 µl
of water/methanol/acetonitrile (80:10:10, v/v/v) before the LC-
MS/MS analysis. The LC-MS/MS analysis was performed using an
Accela HPLC System (Thermo Fisher Scientific, Waltham, Massa-
chusetts, USA) coupled to a triple quadrupole mass spectrometer
TSQ Quantum Access (Thermo Fisher Scientific, Waltham, Massa-
chusetts, USA) outfitted with electrospray ionization source operat-
ing in negative mode. The chromatographic separation was
achieved using an XBridge C18 column (2.1 mm×30 mm, particle
size 2.5 µm, Waters) at 30°C. The mobile phase was composed by
2 mM ammonium acetate in water/acetonitrile/methanol (87:10:3,
v/v/v, at pH8 by ammonium hydroxide) (solvent A) and 2 mM
ammonium acetate in acetonitrile/water/methanol (87:10:3, v/v/v,
at pH8 by ammonium hydroxide) (solvent B). The following gradi-
ent, at a flow rate of 250 µl/min, was used: 0 min—10% B, 2 min
—35% B, 2.5 min—90% B, 6 min—90% B, 6.5 min—10% B, and
12 min—10% B. The analytes were detected by multiple reaction
monitoring, and the transitions monitored (precursor ion >
product-fragment ions) were m/z 295.1 ? m/z 276.8, 194.9
(13HODE) and m/z 299.1 ? m/z 279.9, 197.8 (d4-13HODE). A
linear 6-point calibration curve (range 2–62.5 pg/µl) was used for
the quantification.
Biopsy sampling
Endomyocardial biopsy sampling was performed in ACM-suspected
patients for diagnostic purposes, guided by CARTO mapping, as
previously described (Casella et al, 2015; Pilato et al, 2018). A
biopsy sample from the RV acquired in the area adjacent to the elec-
troanatomical scar was obtained from ACM patients and was
processed to obtain heart sections, total tissue protein extracts, and
C-MSC (Sommariva et al, 2016). HC RV autoptic samples were
treated with the same protocols.
Heart tissue section preparation and
immunofluorescence analysis
Human ventricular samples were fixed in 4% paraformaldehyde
(Santa-Cruz, Dallas, Texas, USA) in phosphate-buffered saline (PBS;
Lonza, Basel, Switzerland) and processed for paraffin embedding.
Paraffin-embedded sections (6 lm thick) were de-waxed in xylene
and rehydrated in ascending alcohols. The immunofluorescence
analysis was performed following antigen retrieval with incubation
with target retrieval solution citrate pH6/microwave (Dako, Santa
Clara, California, USA). Sections were incubated with primary anti-
body anti-MDA (1:2,500; Abcam, Cambridge, UK) and anti-CD36
(1:200; BD, Franklin Lakes, New Jersey, USA) at 4°C overnight (see
Appendix Table S7). After washing, sections were incubated with
the fluorochrome-conjugated antibody goat anti-rabbit IgG Alexa 488
1:200 (Alexa Fluor, Waltham, Massachusetts, USA) for 1 h at room
temperature (RT) in the dark. Nuclear staining was performed by
incubating sections with Hoechst 33342 (1:1,000; Life Technologies,
Carlsbad, California, USA). Sections were observed by Zeiss Axio
Observer.Z1, with Apotome technology, and images were acquired
with the software AxioVision Rel. 4.8. For each explanted heart
subject, three consecutive slices and at least five fields for each slice
were examined, excluding autofluorescence and aspecific signals.
For ACM biopsy samples, all the samples were sliced and examined.
C-MSC isolation and culture
C-MSCs were isolated and cultured as previously reported (Som-
mariva et al, 2016; Pilato et al, 2018). Briefly, ventricular samples
were washed with PBS, cut into 2–3 mm pieces, and incubated at
37°C for 1.5 h under continuous agitation in Iscove’s modified
Dulbecco’s media (IMDM; Gibco, Waltham, Massachusetts, USA)
containing 3 mg/ml collagenase NB4 (Serva, Heidelberg, Germany).
The digested solution was then centrifuged at 400 g for 10 min,
washed with PBS, and centrifuged again. The obtained pellet was
resuspended in GM, consisting of IMDM supplemented with 20%
fetal bovine serum (FBS; Euroclone, Milan, Italy), 10 ng/ml basic
fibroblast growth factor (R&D Systems, Minneapolis, Canada),
10,000 U/ml penicillin (Invitrogen, Carlsbad, California, USA),
10,000 µg/ml streptomycin (Invitrogen, Carlsbad, California, USA),
and 20 mmol/l L-Glutamine (Sigma-Aldrich, St. Louis, Missouri,
USA). The cells were seeded onto uncoated Petri dishes (Corning,
Corning, New York, USA). Non-adherent cells were removed
after 24 h.
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The use of different C-MSC samples for different experiments is
detailed in Appendix Table S6.
C-MSC immunofluorescence analysis
C-MSC were plated on 1.8 cm2 chamber slides (Thermo
Fisher Scientific, Waltham, Massachusetts, USA) at a density of
20,000 cells/cm2. After 24 h of culture in basal conditions, C-MSC
were washed with PBS and fixed in 4% paraformaldehyde in
PBS. After the blocking step in 10% goat serum (Sigma-Aldrich,
St. Louis, Missouri, USA), cells were incubated with primary anti-
bodies anti-MDA (1:2,500; Abcam, Cambridge, UK) and anti-CD36
(1:200; BD, Franklin Lakes, New Jersey, USA) at 4°C overnight.
After washing, sections were incubated with the fluorochrome-
conjugated antibody goat anti-rabbit IgG Alexa 488 1:200
(Alexa Fluor, Waltham, Massachusetts, USA) for 1 h at RT in
the dark. Nuclear staining was performed by incubating sections
with Hoechst 33342 (1:1,000; Life Technologies, Carlsbad, Califor-
nia, USA). Sections were observed by Zeiss Axio Observer.Z1,
with Apotome technology, and images were acquired with
the software AxioVision Rel. 4.8. For each dish, 15 fields were
examined.
C-MSC treatments
The medium used to prompt the adipogenic differentiation of C-
MSC consists of IMDM supplemented with 10% FBS (Euroclone,
Milan, Italy), 0.5 mmol/l 3-isobutyl-1-methylxanthine (Sigma-
Aldrich, St. Louis, Missouri, USA), 1 µmol/l hydrocortisone (Sigma-
Aldrich, St. Louis, Missouri, USA), 0.1 mmol/l indomethacin
(Sigma-Aldrich, St. Louis, Missouri, USA), 10,000 U/ml penicillin
(Invitrogen, Carlsbad, California, USA), 10,000 µg/ml streptomycin
(Invitrogen, Carlsbad, California, USA), and 20 mmol/l L-Glutamine
(Sigma-Aldrich, St. Louis, Missouri, USA). For the preparation of
AM, refer to (Pilato et al, 2018).
C-MSC were plated in AM at a concentration of 20,000 cells/cm2
and treated with 150 lg/ml oxLDL (see the paragraph “oxLDL
preparation”) (Asmis & Begley, 2003; Hamel et al, 2008; Lee et al,
2010), 20 lg/ml 13HODE (Cayman Chemicals, Ann Arbor, Michi-
gan, USA) (Nagy et al, 1998; Kim et al, 2013), or 5 mmol/l NAC
(Sigma-Aldrich, St. Louis, Missouri, USA) (Zolkipli et al, 2011;
Wang et al, 2015; Mao et al, 2016; Pieralisi et al, 2016), a known
thiolic antioxidant (Sunitha et al, 2013). After 72 h, treatment
effects were evaluated by ORO (Sigma-Aldrich, St. Louis, Missouri,
USA) staining and Western blotting analysis.
C-MSC lipid staining
C-MSC were plated at a concentration of 20,000 cells/cm2 and
cultured in AM. Fat accumulation was tested by ORO (Sigma-
Aldrich, St. Louis, Missouri, USA) intracellular lipid staining. In
detail, C-MSC were stained with 1% ORO (Sigma-Aldrich, St. Louis,
Missouri, USA) solution in 60% isopropanol for 1 h after 5-min fixa-
tion with 4% paraformaldehyde in PBS. After five washes in PBS to
ensure the removal of unbound dye, quantitative results were
obtained by evaluating luminance in the 255 red channel with the
ImageJ program (at least 15 fields were evaluated per condition
per patient).
OxLDL preparation
Fresh plasma purchased from healthy donors (Niguarda Ca’ Granda
Hospital, Milano) was brought to a density of 1.019 g/ml with KBr
and subsequently centrifuged at 40,000 rpm for 16 h to remove
VLDL particles. After this operation, the gradient was adjusted to a
density of 1.063 g/ml and samples centrifuged for further 24 h at
the same speed. LDL were then isolated, dialyzed for 48 h at 4°C,
sterilized by filtration (0.22 lm; Millipore, Burlington, Massachu-
setts, USA) and then characterized for their protein and cholesterol
content. Aliquots of 2–3 ml were oxidized by addition of an equal
volume of CuSO4 (final concentration 2.7 mM) for 18 h, under stir-
ring. Oxidation was documented by agarose gel electrophoresis and
by gas-liquid chromatography analysis, by which we monitored the
specific disappearance of polyunsaturated fatty acids, namely lino-
leic, arachidonic, and eicosapentaenoic ones. OxLDL were then
utilized for cell culture experiments, under sterile conditions.
OxLDL internalization assay in C-MSC
C-MSC were plated on 1.8 cm2 chamber slides (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) at a density of 20,000
cells/cm2 either in GM or in AM for 3 days. 10 lg/ml DiI-oxLDL
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) were
added. After 3 h, the cells were fixed for 5 min in 4% paraformalde-
hyde in PBS, stained with Hoechst 33342 (1:1,000; Life Technolo-
gies, Carlsbad, California, USA), and the slides mounted. Pictures
were acquired with Zeiss Axio Observer.Z1, with Apotome technol-
ogy. For the quantification of intracellular DiI, other cells from the
same cultures were treated as described above and acquired with
FACS Gallios (Beckman Coulter, Brea, California, USA).
PKP2 silencing
HC C-MSC were plated at a density of 12,500 cell/cm2 in growth
medium and transduced with pooled lentiviral particles containing
shRNAs targeting both variants of human PKP2 (Gene ID 5381) in
psi-LVRU6GP (with U6 promoter, eGFP reporter, puromycin resis-
tance; Genecopoeia; Rockville, Maryland) or with the correspondent
scrambled control lentiviral particles (Genecopoeia; Rockville,
Maryland) for 24 h. After checking the transduction efficiency by
detection of the GFP signal, 2 lg/ml puromycin was added to select
transduced cells.
After cell amplification, PKP2 reduction was assayed by Western
blot. Scrambled control and PKP2 shRNA C-MSC were plated in AM
at a concentration of 20,000 cells/cm2 and treated with 150 lg/ml
oxLDL. After 72 h, treatment effects were evaluated by Oil Red O
(ORO; Sigma-Aldrich St. Louis, Missouri, USA) staining.
CD36 knockdown in C-MSC
C-MSC were cultured for 24 h in low-serum medium without antibi-
otics (IMDM, 2% FBS (Euroclone, Milan, Italy) and 20 mmol/l L-
Glutamine (Sigma-Aldrich, St. Louis, Missouri, USA). 0.05 µM of
Human Silencer Select Pre-designed CD36 siRNA (4392422-S2646
siRNA; Life Technologies, Carlsbad, California, USA) or 0.05 µM
Silencer Select Negative Control (4390844 scramble; Life Technolo-
gies, Carlsbad, California, USA) and 4 µl lipofectamine RNAiMAX
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(Life Technologies, Carlsbad, California, USA) were added to 300 µl
of Opti-MEM medium (Life Technologies, Carlsbad, California,
USA). After 15 min at RT, the transfection reactions were added to
the cells in 1.5 ml low-serum/no antibiotics medium. After 24 h,
the medium was changed to AM supplemented with 150 µg/ml
oxLDL for the following 72 h. CD36 reduction was confirmed by
Western blot at the end of the experiment.
PPARc antagonism in C-MSC
C-MSC were cultured for 72 h in AM with 5 lM GW9662 (Sigma-
Aldrich, St. Louis, Missouri, USA). The treatment was added to the
medium every 8 h. To check oxLDL internalization, 10 lg/ml DiI-
oxLDL (Thermo Fisher Scientific, Waltham, Massachusetts, USA)
were added 3 h before the end of the experiment, following the
protocol described above (see “OxLDL internalization assay”).
Pictures were acquired with Zeiss Axio Observer.Z1, with Apotome
technology, and images were acquired with the software AxioVision
Rel. 4.8. For each biological sample, 15 fields were examined.
Flow cytometry in C-MSC
To evaluate C-MSC oxidative status, cells cultured in basal medium
were incubated for 30 min with 10 lM dichlorofluorescein (Sigma-
Aldrich, St. Louis, Missouri, USA) and detached with TrypLE Select
(Life Technology, Carlsbad, California, USA), and the conversion
into the fluorescent dye 20,70-DCF by cell ROS was measured by flow
cytometry (Gallios, Beckman Coulter, Brea, California, USA). The
mean FITC fluorescence was measured.
To determine the correlation between CD36 expression and lipid
accumulation, cells were stained using 12.5 ng/ml Nile Red (Invitro-
gen, Carlsbad, California, USA), to mark intracellular neutral lipids,
and 2.5 ll of anti-CD36 antibody (Life Technologies, Carlsbad, Cali-
fornia, USA). The mean of the fluorescence was determined for Nile
Red and CD36 for each sample.
To quantify the DiI-oxLDL internalization, cells were treated with
10 lg/ml DiI-oxLDL for 3 h, detached with TrypLE Select (Life
Technologies, Carlsbad, California, USA), and acquired with FACS
Gallios (Beckman Coulter, Brea, California, USA). The mean APC
fluorescence was determined for each sample.
Western blot in C-MSC
Total proteins from C-MSC were obtained by Laemmli lysis buffer.
After quantification with DC protein assay (Bio-Rad, Hercules, Cali-
fornia, USA), proteins were run on SDS–PAGE gel (NUpage precast
4–12%; Invitrogen, Carlsbad, California, USA) and transferred to
nitrocellulose membrane (Bio-Rad, Hercules, California, USA). The
membrane was blocked in 5% skimmed milk-TBS for 1 h at RT and
incubated overnight at 4°C with primary antibodies against GAPDH,
PPARc, and CD36 (see Appendix Table S7). After washes, the
membrane was incubated for 1 h at RT with the appropriate HRP-
conjugated secondary antibody goat anti-rabbit or goat anti-mouse
(GE Healthcare, Chicago, Illinois, USA). Blots were washed and
developed with the ECL system (Bio-Rad, Hercules, California,
USA). Images were acquired with the Alliance Mini 2 M System
(UVITEC, Cambridge, UK), and densitometric analysis was
performed using Alliance Mini4 16.07 software (UVITEC,
Cambridge, UK). Data are normalized expressing as 1 the compar-
ison group in order to highlight the fold differences between dif-
ferent groups or treatment.
Glutathione quantification in C-MSC
Levels of GSH and GSSG were determined by a previously described
and validated LC-MS/MS method (Squellerio et al, 2012). Briefly,
cells cultured in GM have been washed twice with PBS, detached
with trypsin, and then collected and centrifuged at 400 g for 10 min.
The supernatant was removed, the pellet was resuspended in 50 µl
of PBS, and proteins were precipitated with 50 µl of 10% trichloroa-
cetic acid with the addition of 1 mmol/l EDTA and stored at 80°C
until the analysis. Thawed samples were further diluted 1:10 with
formic acid 0.1% before the LC-MS/MS analysis. The LC-MS/MS
analysis was performed using an Accela HPLC System (Thermo
Fisher Scientific, Waltham, Massachusetts, USA) coupled to a triple
quadrupole mass spectrometer TSQ Quantum Access (Thermo
Fisher Scientific, Waltham, Massachusetts, USA) outfitted with elec-
trospray ionization source operating in positive mode. The chro-
matographic separation was conducted on a Luna PFP column
(2.0 mm × 100 mm, particle size 3.0 µm, Phenomenex, Torrance,
California, USA) maintained at 35°C. Analytes were eluted under
isocratic conditions at 200 µl/min by 1% methanol in 0.75 mM
ammonium formate adjusted to pH3.5 with formic acid. The
analytes were detected by multiple reaction monitoring, and the
transitions monitored (precursor ion > product-fragment ions) were
m/z 308.1 ? m/z 76.2, 84.2, 161.9 (GSH) and m/z 613.2 ? m/z
230.5, 234.6, 354.8 (GSSG). A linear 6-point calibration curve (range
0.25–8 µM for GSH and 0.008–0.25 µM for GSSG) was used for the
quantification.
Analysis of C-MSC lipids
Cell lipids were extracted by hexane/isopropanol 3:2, plus butylated
hydroxytoluene 0.005% as antioxidant. Known amounts of proper
internal standards (stigmasterol, cholesteryl heptadecanoate, trihep-
tanoin, nonadecanoic acid; Sigma-Aldrich, St. Louis, Missouri, USA)
were added for the analysis of free cholesterol (FC) and esterified
cholesterol (CE), triglycerides (TG), and free fatty acids (FFA),
respectively. Lipid extracts were dried in a steam of nitrogen,
aliquoted, and conserved at 80°C in the dark, until use.
An aliquot was loaded onto pre-run and activated channeled
Silica TLC plates (BioMap) and run in hexane-diethyl ether-acetic
acid (80:20:1 vol/vol/vol). The plates were then sprayed with
dichlorofluorescein (0.15% in ethanol), and the spots corresponding
to those of FC, FFA, TG, and CE standards were identified by UV
light and scraped out of the TLC.
Samples were analyzed by a gas-liquid chromatographer (GLC
1000; DANI Instruments, Cologno Monzese, Italy) equipped with an
autosampler HT300A (HTA, Brescia, Italy), a fused silica column
(MEGA-5 30 m length, 0.3 mm diameter, 0.15 µm film thickness;
Mega Columns, Legnano, Italy) and a flame ionization detector.
Hydrogen flow was at a constant pressure of 1.2 bar. The oven
temperature was constant (260°C, 8 min run) for FC, while ranged
from 120°C to 300°C for FFA, TG, and CE (total run 45 min).
FC was resuspended in hexane/isopropanol and analyzed with-
out derivatization. The other lipid classes were processed with
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methanolic acid 3N at 30–80°C for 30–120 min and analyzed for
their fatty acid content. Peaks were identified by comparing their
retention times with those of standard and their area determined by
a dedicated software (Clarity). To calculate the total mass of each
lipid class, the areas of all the peaks corresponding to the fatty acids
were summed and the real mass determined by comparison with
the area of the internal standards. Results were normalized by the
number of cells in each dish (µg lipid/106 cells).
Generation of ACM and HC hiPSC
hiPSC from one ACM patient, carrying the deletion of the
whole PKP2 exon 4 leading to a predicted truncated protein
(p.N346Lfs*12), and one HC of the same family were obtained and
characterized as previously described (Ermon et al, 2018; Merav-
iglia et al, 2018). Briefly, every hiPSC line has been generated using
episomal vectors carrying OCT3/4, SOX2, KLF4, and L-MYC and has
been subsequently grown on a mouse embryonic fibroblast (MEF)
feeder layer. Clones that passed the quality check were adapted at
passage 10–15 to grow in feeder-free condition (without MEF)
directly onto six-well plates coated with Matrigel matrix (Corning,
Corning, New York, USA) and cultured in the commercially avail-
able xeno-free medium StemMACSTM iPS-Brew XF (Miltenyi Biotec,
Bergisch Gladbach, Germany).
Cardiomyogenic differentiation of hiPSC
hiPSC were propagated on Matrigel (Corning, Corning, New York,
USA)-coated plates, and the cardiomyogenic differentiation was
performed using PSC Cardiomyocyte Differentiation Kit (Thermo
Fisher Scientific, Waltham, Massachusetts, USA). After 30 days,
cardiomyocytes were dissociated at single cells using Multi Tissue
Dissociation Kit 3 (Miltenyi Biotec, Bergisch Gladbach, Germany)
and enriched by magnetic separation with the QuadroMACSTM
Separator and PSC-Derived Cardiomyocyte Isolation Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cells were then maintained
in culture for additional 25 days in the following different condi-
tions: growth medium (composed by High Glucose DMEM (Gibco,
Waltham, Massachusetts, USA), 2% of Hyclone Fetal Bovine
Defined (GE Healthcare, Chicago, Illinois, USA), 1% of Non-
Essential Amino Acids, Penicillin/Streptomycin and 0,09% of b-
mercaptoethanol), and Adipogenic Medium (growth medium
supplemented with 50 lg/ml Insulin (Sigma-Aldrich, St. Louis,
Missouri, USA), 0.5 lM Dexamethasone (Sigma-Aldrich, St. Louis,
Missouri, USA), 0.25 mM 3-isobutyl-1 methylxanthine (IBMX)
(Sigma-Aldrich, St. Louis, Missouri, USA), 200 lM Indomethacin
(Sigma-Aldrich, St. Louis, Missouri, USA) with 5 lM Rosiglitazone
(Vinci-Biochem, Vinci, Italy). The culture medium was changed
every other day. Cells were analyzed through immunofluorescence
and FACS analysis.
hiPSC-CM immunofluorescence analysis
Cells were fixed with 4% paraformaldehyde for 15 min and then
permeabilized (PBS with 0,1% Triton X100) for 10 min at RT. Cells
were then blocked in PBS with 5% Goat serum for 1 h at RT and
incubated with anti-aSARC overnight at 4°C. After washing, cells
were incubated with the proper secondary antibody for 1 h at 37°C.
Intracellular lipid droplet accumulation was evaluated using BODIPY
493/503 assay (dilution 0.1 µg/ml in PBS; Thermo Fisher Scientific,
Waltham, Massachusetts, USA) incubated for 20 min at RT and
nuclei were stained with DAPI (Invitrogen, Carlsbad, California,
USA). The images were acquired using confocal microscopy (Leica
Microsystem CMs GmBH Type: TCSSP8X) and analyzed with ImageJ
software. Intensity fluorescence was normalized on nuclei number.
hiPSC-CM flow cytometry analysis
Cells were dissociated at single cell using Multi Tissue Dissociation
Kit 3 (Miltenyi Biotec, Bergisch Gladbach, Germany), following the
manufacturer’s instructions and blocked in FACS buffer (PBS
containing 0.5% FBS and 2 mM EDTA). Cells were incubated with
anti-CD36 for 15 min at 4°C avoiding direct light and then washed
and resuspended with FACS buffer. Cardiomyocytes were identified
and gated based on their forward and side scatter using the S3Cell
Sorter (Bio-Rad, Hercules, California, USA); median fluorescence
intensity (MFI) of PE was calculated on the gated cells. Data were
analyzed using FlowJo software. Median intensity fluorescence is
presented as MFI(PE) sample – MFI(PE) isotype.
ACM murine model: Pkp2+/ mice
C57Bl/6 Pkp2 heterozygous knock-out mice (Pkp2+/) were
produced by Prof. Birchmeier, as described (Grossmann et al,
2004). The homozygous mice were embryonic-lethal, while
heterozygous mice were healthy and fertile. For our experiments,
we used 28 C57Bl/6 Pkp2+/ mice and 28 siblings C57Bl/6 wild
type (WT), as control. This number is the result of a power analysis
by means of G*Power 3.1.9.2 software. We used a two-way ANOVA
test, taking into account the interaction between the differences due
to the different strains to be used, and that due to the diets. Thanks
to previous results with the same murine model, given the expected
differences in cardiac lipid accumulation and the expected inter-
group standard deviation, we obtained an effect size f of 0.52. The
calculation of sample size showed that ˜9 animals/group/treatment
are required for an 85% probability of demonstrating differences
from the mean, with a P value of 0.05.
Experiments were authorized on 27/07/2015 by the Italian
Ministry of Health, protocol no. 779/2015-PR.
Murine C-MSC isolation and culture
Explanted hearts from 5 WT and 5 Pkp2+/ mice (age: 10 weeks)
were washed with PBS, cut into 2–3 mm pieces, and incubated at
37°C for 1 h under continuous agitation in IMDM containing 3 mg/
ml collagenase NB4. After a PBS wash, the pellet was resuspended
in GM and seeded. Non-adherent cells were removed after 24 h. AM
medium was used to prompt the adipogenic differentiation of
murine C-MSC for 6 days.
High-fat diet
10 WT and 10 Pkp2+/ mice (age: 10 weeks) were fed for 3 months
with a high-cholesterol (279.6 mg/kg) and high-fat (60% kcal) diet
(HFD; OpenSource DIETS, New Brunswick, New Jersey, USA)
(Khan-Merchant et al, 2002).
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9 WT and 9 Pkp2+/ mice were fed with chow diet (CD; Open-
Source DIETS, New Brunswick, New Jersey, USA).
Heart volumes and functionality were assessed before the begin-
ning of the diet and every month by echocardiography. Bodyweight
was monitored every month. Blood samples were taken before and
after the diet. At sacrifice, hearts were explanted after perfusion
with saline solution. Sections of heart specimens were used for lipid
accumulation analysis, PPARc, MDA, and CD36 immunofluores-
cence staining. Protein extracts from total tissue lysates were used
to evaluate PPARc, MDA, and CD36 expression through Western
blot analysis.
High-fat diet plus atorvastatin
Nine WT and 9 Pkp2+/ mice (age: 10 weeks) were fed for
3 months with a HFD (D12492, Open Source, New Brunswick,
New Jersey, USA) to which 20 mg/kg atorvastatin (Khan et al,
2018; Peng et al, 2018) was added. Heart volumes and function-
ality were assessed before the beginning of the diet and every
month by echocardiography. Bodyweight was monitored every
month. Blood samples were taken before and after the diet. At
sacrifice, hearts were explanted after perfusion with saline solu-
tion. Sections of heart specimens were used for lipid accumula-
tion analysis, PPARc, MDA, and CD36 immunofluorescence
staining. Protein extracts from total heart tissue lysates were used
to evaluate PPARc, MDA, and CD36 expression through Western
blot analysis.
Echocardiographic and electrocardiographic analyses
Transthoracic echocardiography was performed using the Vevo2100
high-resolution imaging system (VisualSonics, Toronto, Canada)
and a 40-MHz linear transducer with simultaneous electrocardio-
graphic recording, as previously reported (Milano et al, 2014). Anal-
yses were performed on mice lightly anesthetized with 0.5% to 1%
isoflurane (heart rate: 480–550 beats/min) at the following time-
points: 1 day before starting the diet (pre-diet) and on 1, 2, and
3 months of CD, HFD or HFD+atorva.
RV parameters in systole and diastole were acquired from a
parasternal long-axis view and measured from images acquired in
M mode, using the depth interval (in mm) generic measurements
tool (Urboniene et al, 2010; Seta et al, 2011; Hansmann et al,
2012).
Two-dimensional short-axis M-mode echocardiography was
performed at the level of the midpapillary muscle to measure LV
parameters, in systole and diastole.
All measurements were averaged from a minimum of three
cycles during diastole and systole corresponding to the electrocar-
diogram. Data and imaging were analyzed using the VisualSonics
Cardiac Measurements Package by a blinded investigator. Parame-
ters were normalized on mice heart weight.
Surface electrocardiographic signal (lead II via limb electrodes)
were acquired in all mice during echocardiography (lightly anes-
thetized mice). CSV files of each mouse physiological data were
exported, and analyzed in Excel. Specifically, QRSp (as defined in
(Merentie et al, 2015)), terminal activation duration (TAD) and QRS
amplitude were measured in at least 10 consecutive beats for each
animal by a blinded investigator.
Murine blood sampling
Mice were anesthetized with 4% isoflurane and maintained asleep
with 1% isoflurane. The blood sampling was performed through tail
vein using 25G needle, after tail pre-heating and local application of
anesthetic.
Whole blood was collected into EDTA-coated tubes (Fisher Scien-
tific, Waltham, Massachusetts, USA). Separated plasma was
obtained after centrifugation for 15 min at 2,000 g at 4°C and stored
at 80°C until the analysis.
Total cholesterol distribution in lipoproteins from mouse plasma
50 ll of mouse plasma has been injected twice in a HPLC system
(Jasco 920; Jasco, Cremella, Italy), with a pre-column (6 mm ID ×
4 cm; Tosoh, Tokyo, Japan), two consecutive inverse phase, size-
exclusion, anionic-exchange TSK-GEL LIPOPROPAK XL (7.8 mm ID ×
30 cm) columns (Tosoh, Tokyo, Japan) and with a UV-VIS detector
(Jasco, Cremella, Italy). Readings were performed at a 280 nm. The
mobile phase consisted of 6.9 g of sodium monobasic phosphate,
50 mg BRIJ, and 30 ml isopropanol per liter (pH8).
We divided each sample into 50 fractions (one every minute),
and we collected those from #22 to #45, corresponding to VLDL,
IDL, LDL, and HDL. Each obtained fraction (1 ml) was frozen at
80°C, lyophilized, and then reconstituted with 200 ll of
water. On portions of these samples, total cholesterol was
measured by commercial colorimetric kits (ABX Pentra, Roma,
Italy) at 490 nm by a spectrophotometer (Bio-Rad, Hercules, Cali-
fornia, USA).
oxLDL in murine plasma samples
For the quantitative determination of oxLDL in murine plasma
samples before and after the HFD or HFD+atorva, Mouse Oxidized
Low Density Lipoprotein ELISA kit was used (CUSABIO, Houston,
Texas, USA), following the manufacturer’s instructions. Absor-
bance was determined with a spectrophotometer (Berthold Tech-
nologies, Bad Wildbad, Germany) at 450 nm. Results were
inferred according to a calibration curve constructed using the
standards provided in the kit.
Histological characterization of Pkp2+/ hearts
Explanted hearts from WT and Pkp2+/ mice, in CD, HFD, and
HFD+atorva conditions, were fixed in 4% paraformaldehyde
(Santa-Cruz, Dallas, Texas, USA) overnight at 4°C. The following
day, after three washes in PBS, the hearts were transferred in 15%
sucrose in distilled water overday at RT and then in 30% sucrose
in distilled water overnight at 4°C. The explanted hearts were
embedded in OCT (Thermo Fisher Scientific, Waltham, Massachu-
setts, USA) and stored at 80°C until use. After sectioning with a
cryostat (Thermo Fisher Scientific, Waltham, Massachusetts, USA),
OCT embedded sections (6 lm thick) were de-frosted and washed
twice in PBS. The immunofluorescence analysis was performed
following blocking in 2% goat serum (Sigma-Aldrich, St. Louis,
Missouri, USA) for 30 min. Sections were incubated with primary
antibodies (see Appendix Table S7) anti-PPARc (1:200; Life Tech-
nologies, Carlsbad, California, USA), anti-MDA (1:2,500; Abcam,
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Cambridge, UK), anti-CD36 (1:200, Neuromics, Edina, Minneapolis,
USA), anti-CD105 (1:40, R&D System, Minneapolis, Minnesota,
USA), anti-troponin T (1:100, Abcam, Cambridge, UK), anti-
perilipin1 (1:100, OriGene, Rockville, Maryland, USA), and anti-
CX43 (1:400, Abcam, Cambridge, UK) at 4°C overnight. After wash-
ing, sections were incubated with the fluorochrome-conjugated
antibodies goat anti-rabbit IgG Alexa 488 (1:200; Alexa Fluor,
Waltham, Massachusetts, USA), Streptavidin-Alexa Fluor 594
(1:200; Alexa Fluor, Waltham, Massachusetts, USA), goat anti-
rabbit 546 (1:200; Alexa Fluor, Waltham, Massachusetts, USA),
and goat anti-guinea pig 488 (1:200; Alexa Fluor, Waltham, Massa-
chusetts, USA) for 1 h at RT in the dark. Nuclear staining was
performed by incubating sections with Hoechst 33342 (1:1,000; Life
Technologies, Carlsbad, California, USA). Sections were observed
with Zeiss Axio Observer.Z1, with Apotome technology, and
images were acquired with the software AxioVision Rel. 4.8. For
each explanted heart, at least 10 fields for five consecutive
transversal slices were quantified.
For the lipid accumulation analysis, the sections were stained
with ORO (Sigma-Aldrich, St. Louis, Missouri, USA) for 1 h at RT
and then washed five times in PBS to ensure the removal of the
aspecific dye. Quantitative results were obtained by evaluating red
area vs. total tissue area (all the section surface of five consecutive
slices for each sample was quantified).
Western blot in murine total heart tissue
Total proteins from murine total heart tissue lysates were obtained
by Laemmli lysis buffer. After quantification with DC protein assay
(Bio-Rad, Hercules, California, USA), proteins were run on SDS–
PAGE gel (NUpage precast 4–12%; Invitrogen, Carlsbad, California,
USA) and transferred to nitrocellulose membrane (Bio-Rad,
Hercules, California, USA). The membrane was blocked in 5%
skimmed milk-TBS for 1 h at RT and incubated overnight at 4°C
with primary antibodies against GAPDH, PPARc, MDA, and CD36
(see Appendix Table S7). After washes, the membrane was incu-
bated for 1 h at RT with HRP-conjugated secondary antibody goat
anti-rabbit (GE Healthcare, Chicago, Illinois, USA). Blots were
washed and developed with the ECL system (Bio-Rad, Hercules,
California, USA). Images were acquired with the Alliance Mini 2 M
System (UVITEC, Cambridge, UK), and densitometric analysis
was performed using Alliance Mini4 16.07 software (UVITEC,
Cambridge, UK). Data are normalized expressing as 1 the compar-
ison group in order to highlight the fold differences between dif-
ferent groups or treatment.
Patient fat infiltration analysis at MRI
Intramyocardial fat mass was evaluated as previously described
(Aquaro et al, 2012; Aquaro et al, 2014). Briefly, steady-state free
procession (SSFP) were used and the following acquisition param-
eters were applied: 30 phases, 10–25 views per segment, NEX 1,
FOV 40 cm, a matrix of 224 x 224, a 60° flip angle, TR 3.6–4.2
and TE = TR/2. Images were acquired using a 1.5-T unit (Discov-
ery MR450, GE Healthcare, Milwaukee, Minneapolis, USA). Fat in
the ventricular myocardium appears as a hyperintense area
surrounded by a hypointense band, the so-called chemical shift
artifact (Aquaro et al, 2014). Manual contouring of the chemical
shift artifact (including the black contour) was drawn, and its
extent was measured.
Statistical analysis
Discrete variables were analyzed with Fisher’s exact test. Continuous
variables were reported as meanstandard error. Comparisons
between normally distributed groups were performed using either
paired or unpaired two-tailed Student’s t-tests, whereas populations
without a Gaussian distribution were compared using Mann–Whitney
tests. The n indicated in each figure legend corresponds to biological
replicates. Comparisons among three or more groups were performed
with one-way or two-way ANOVA test, in association with Bonferroni
multiple comparison post-tests.When both intragroup and intergroup
values are tested, red lines and asterisks identify test differences
within the same group, while intergroup differences are in black. X-Y
correlation analyses have been determined. Comparison of slopes of
linear regressions was performed with the following method:
t = (b1–b2) / sb1,b2 where b1 and b2 are the two slope coefficients
and sb1,b2 the pooled standard error of the slope. Receiver operating
characteristic (ROC) plot was used to determine the oxLDL level cut-
off valueminimizing the difference between sensitivity and specificity
in discriminating ACM patients vs. HC individuals. Kaplan–Meier
curves were performed to determine the actual risk of MAE and
analyzed through log-rank (Mantel–Cox) test. Statistics were
performed using GraphPad Prism software. Results were considered
statistically significant for P values < 0.05 (see Appendix Table S8 for
the details). Power analyses, for both in vitro and in vivo experi-
ments, were performed using G*Power 3.1.9.2 software.
The Paper Explained
Problem
Arrhythmogenic cardiomyopathy (ACM) is a genetically determined
heart condition. It is hallmarked by a gradual fibro-adipose replace-
ment of the ventricular myocardium, heart failure, malignant arrhyth-
mias, and sudden death. Few information is available regarding the
mechanisms mediating the phenotypic variability among carriers of
the same ACM mutation. In addition, no pharmacological approaches
are available in the clinical practice to counteract cardiac adipogenic
substitution.
Results
We demonstrated that oxLDL increase ACM adipogenesis through a
mechanism implying over-activation of PPARc, the main effector of
lipid accumulation. This novel pathogenic mechanism was investi-
gated in patients and verified with in vitro experiments on two
cardiac cell types and in vivo studies. Importantly, antioxidants and
atorvastatin treatments counteracted ACM phenotypes.
Impact
This study adds a piece to the puzzle of phenotypic variability among
carriers of the same ACM mutation. Increased oxLDL plasma levels
may represent both a precision medicine tool to identify patients at
high disease burden and a target of therapeutic approaches. A proof
of principle is given of the efficacy of a new treatment with atorvas-
tatin and antioxidants in counteracting oxidized lipid-dependent
cardiac adipogenesis and related dysfunction. Future drug reposition-
ing studies will compare the efficacy of such treatments in mitigating
ACM phenotypes.
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Data availability
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Expanded View for this article is available online.
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